Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction- based assay

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 619-626

  Bostic, Jennifer Reed ^a,b   Brown, Kevin E ^a,b   Young, Neal S ^a,b   Koenig, Scott ^a,b  

^a MEDIMMUNE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CAPSID PROTEIN; CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN G; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIBODY TITER; ARTICLE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS TRANSCRIPTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CAPSID; CAPSID PROTEINS; CELL LINE; ERYTHEMA INFECTIOSUM; GUINEA PIGS; HUMANS; IMMUNOGLOBULIN G; MACACA MULATTA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL VACCINES;

EID: 0033380375     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314648     Document Type: Article

References (29)

1. 1. Cossart YE, Field A, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975;1:72-3.
2. 2. Brown KE, Young NS, Liu JS. Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol 1994;16:1-31,
3. 3. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989;149:1153-6.
4. 4. Kelleher JF, Luban NL, Mortimer PP, Kamimura T. Human serum "parvovirus": a specific cause of aplastic crisis in children with hereditary spherocytosis. J Pediatr 1983;102:720-2.
5. 5. Neild G, Anderson M, Hawes S, Colvin BT. Parvovirus infections after renal transplant [letter]. Lancet 1986;2:1226-7.
6. 6. Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987;316:183-6.
7. 7. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987;317:287-94.
8. 8. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red cell aplasia of ten years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-23.
9. 9. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type I (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926-33.
10. 10. Seyama K, Kobayashi R, Hasle H, et al. Parvovirus B19 induced anemia as the presenting manifestation of X-linked hyper-IgM syndrome. J Infect Dis 1998;178:318-24.
11. 11. Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989;84:1114-23.
12. 12. Takahashi M, Koike T, Moriyama Y, Shibata A. Neutralizing activity of immunoglobulin preparation against erythropoietic suppression of human parvovirus [letter]. Am J Hematol 1991;37:68.
13. 13. Kajigaya S, Fugii H, Field A, et al. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci USA 1991;88:4646-50.
14. 14. Rosenfeld SJ, Yoshimoto K, Kajigaya S, et al. The region unique to the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest 1992;89:2023-9.
15. 15. Bansal GP, Hatfield JA, Dunn FF, et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993;167:1034-44.
16. 16. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, van Nest G, Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, eds. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995;277-95.
17. 17. Newman MJ, Balusubramanian M, Todd CW. Development of adjuvant-active nonionic block copolymers. Adv Drug Delivery Rev 1998;32: 199-223.
18. 18. Shimomura S, Komatsu N, Frickhofen N, Anderson S, Kajigaya S, Young NS. First continuous propagation of B19 parvovirus in a cell line. Blood 1992;79:18-24.
19. 19. Komatsu N, Yamamoto M, Fujita H, et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line. Blood 1993;82:456-64.
20. 20. Ozawa K, Ayub J, Hao YS, Kurtzman G, Shimada T, Young NS. Novel transcription map for the B19 (human) pathogenic parvovirus. J Virol 1987;61:2395-406.
21. 21. Bansal GP, Hatfield JA, Dunn FE, et al. Immunogenicity studies of recombinant human parvovirus B19 proteins. In: Brown F, Chanock RM, Ginsberg, HS, Lerner RA, eds. Vaccines 92: modern approaches to new vaccines including prevention of AIDS. Plainview, NY: Cold Spring Harbor Laboratory Press, 1992:315-9.
22. 22. Munshi NC, Zhou S, Woody MJ, Morgan DA, Srivastava A. Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J Virol 1993;67:562-6.
23. 23. Takahashi T, Ozawa K, Mitani K, Miyazono K, Asano S, Takaku F. B19 parvovirus replicates in erythroid leukemic cells in vitro [letter]. J Infect Dis 1989;160:548.
24. 24. Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 1998;95:8227-32.
25. 25. Yoshimoto K, Rosenfeld S, Frickhofen N, et al. A second neutralizingepitope of B19 parvovirus implicates the spike region in the immune response. J Virol 1991;65:7056-60.
26. 26. Sato H, Hirata J, Kuroda N, Shiraki H, Maeda Y, Okochi K. Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies. J Virol 1991;65:5485-90.
27. 27. Brown CS, Jensen T, Moeloen RH, et al. Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: correlation to a major surface region on the native virus particle. J Virol 1992;66: 6989-96.
28. 28. Saikawa T, Anderson S, Momoeda M, Kajigaya S, Young NS. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol 1993;67:3004-9.
29. 29. Arakelov S, Gorny MK, Williams C, et al. Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. J Infect Dis 1993;168:580-5.